Developing Story
NECTIN4 and Enfortumab Vedotin in Bladder Cancer
Researchers report that NECTIN4, the target of the drug enfortumab vedotin, acts as a subtype-dependent determinant of tumor state and antitumor immunity in bladder cancer, with NECTIN4-high basal/squamous tumors showing better survival and checkpoint inhibitor response.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
## Overview
NECTIN4 is the molecular target of enfortumab vedotin (EV), an antibody-drug conjugate used in bladder cancer treatment, but its underlying biological role and relationship to combination therapy with PD-1 blockade had remained unclear (bioRxiv, October 9).
## Key Findings
- New research integrating clinical multi-omics, spatial and single-cell immune profiling, and experimental models identifies NECTIN4 as a subtype-dependent determinant of tumor state and antitumor immunity in bladder cancer (bioRxiv, October 9).
- In basal bladder cancer cells, NECTIN4 reportedly suppressed inflammatory and mesenchymal programs; NECTIN4-high basal/squamous muscle-invasive bladder cancers showed favorable survival, higher checkpoint inhibitor response rates, and a coordinated CD8+ T cell-inflamed phenotype (bioRxiv, October 9).
## Why It Matters
These findings could inform biomarker-driven treatment selection for enfortumab vedotin plus checkpoint inhibitor combinations, a therapy regimen with significant commercial and clinical importance in bladder cancer care, making this a topic likely to recur in oncology and pharma coverage.
## Entities Involved
NECTIN4, enfortumab vedotin, PD-1 checkpoint inhibitors, bladder cancer.